| Literature DB >> 32603135 |
Shuaijian Ni1,2,3,4, Zhenjian Zhuo5, Yufei Pan6, Yuanyuan Yu1,2,3,4, Fangfei Li1,2,3,4, Jin Liu1,2,3,4, Luyao Wang1,2,3,4, Xiaoqiu Wu1,2,3,4, Dijie Li1,2,3,4, Youyang Wan1,2,3,4, Lihe Zhang6, Zhenjun Yang6, Bao-Ting Zhang5, Aiping Lu1,2,3,4, Ge Zhang1,2,3,4.
Abstract
Aptamers are oligonucleotide sequences with a length of about 25-80 bases which have abilities to bind to specific target molecules that rival those of monoclonal antibodies. They are attracting great attention in diverse clinical translations on account of their various advantages, including prolonged storage life, little batch-to-batch differences, very low immunogenicity, and feasibility of chemical modifications for enhancing stability, prolonging the half-life in serum, and targeted delivery. In this Review, we demonstrate the emerging aptamer discovery technologies in developing advanced techniques for producing aptamers with high performance consistently and efficiently as well as requiring less cost and resources but offering a great chance of success. Further, the diverse modifications of aptamers for therapeutic applications including therapeutic agents, aptamer-drug conjugates, and targeted delivery materials are comprehensively summarized.Entities:
Keywords: aptamer; aptamer−drug conjugate (ApDC); long-acting modification; microfluidic SELEX; nanoparticle; targeted delivery materials; therapeutic application
Mesh：
Substances：
Year: 2020 PMID： 32603135 DOI： 10.1021/acsami.0c05750
Source DB: PubMed Journal: ACS Appl Mater Interfaces ISSN： 1944-8244 Impact factor: 9.229